Consequences and management of hyperphosphatemia in patients with renal insufficiency

Kidney International, Supplement

Volumn 67, Issue 95, 2005, Pages

  Friedman, Eli A ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM DERIVATIVE; CALCIMIMETIC AGENT; CALCIUM; CALCIUM DERIVATIVE; CALCIUM PYROPHOSPHATE; CINACALCET; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; VITAMIN D; CALCIUM ACETATE; ACETIC ACID DERIVATIVE; PHOSPHATE;

ARTHROPATHY; BONE DEMINERALIZATION; BONE DISEASE; BRAIN DISEASE; CALCIUM BLOOD LEVEL; CARDIOTOXICITY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONSTIPATION; DIET; DISEASE COURSE; DOSE RESPONSE; FRACTURE; HEART DISEASE; HORMONE RELEASE; HUMAN; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPOCALCEMIA; INGESTION; INTESTINE FUNCTION; KIDNEY DISEASE; MICROCYTIC ANEMIA; MINERAL METABOLISM; NAUSEA; NEPHROLOGIST; OSTEOMALACIA; PATHOGENESIS; PRECIPITATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SUBCUTANEOUS TISSUE; VITAMIN BLOOD LEVEL; BONE DESTRUCTION; DRUG SAFETY; JOINT DESTRUCTION; KIDNEY FAILURE; VITAMIN SUPPLEMENTATION; BLOOD; CALCINOSIS; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; MORTALITY; PATHOPHYSIOLOGY; RADIOGRAPHY; RENAL REPLACEMENT THERAPY; SECONDARY HYPERPARATHYROIDISM;

ACETATES; CALCINOSIS; CALCIUM; CARDIOVASCULAR DISEASES; DIET; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE; PHOSPHATES; RENAL DIALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 24944484324     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.09500.x     Document Type: Article

References (29)

1. SUGARMAN JR, FREDERICK PR, FRANKENFIELD DL, et al: Dialysis Outcomes Quality Initiative Clinical Practice Guidelines. Developing clinical performance measures based on the Dialysis Outcomes Quality Initiative Clinical Practice Guidelines: Process, outcomes, and implications. Am J Kidney Dis 42:806-812, 2003
2. MICHAEL M, GARCIA D: Secondary hyperparathyroidism in chronic kidney disease: Clinical consequences and challenges. Nephrol Nurs J 31:185-194, 2004
3. GOODMAN WG: The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. Semin Dial 17:209-216, 2004
4. SILVER J: Pathogenesis of parathyroid dysfunction in end-stage renal disease. Adv Ren Replace Ther 9:159-167, 2002
5. SLATOPOLSKY E, BROWN A, DUSSO A: Pathogenesis of secondary hyperparathyroidism. Kidney Int 73(Suppl):S14-S19, 1999
6. BROWN AJ, DUSSO A, SLATOPOLSKY E: Vitamin D. Am J Physiol 277:F157-F175, 1999
7. MARTINEZ I, SARACHO R, MONTENEGRO J, et al: A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 11(Suppl 3):22-28, 1996
8. SILVER J, KILAV R, NAVEH-MANY T: Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Physiol 283:F367-F376, 2002
9. MOZ Y, SILVER J, NAVEH-MANY T: Characterization of cis-acting element in renal NaPi-2 cotransporter mRNA that determines mRNA stability. Am J Physiol Renal Physiol 284:F663-F670, 2003
10. MALLUCHE HH, MAWAD H, MONIER-FAUGERE MC: The importance of bone health in end-stage renal disease: Out of the frying pan, into the fire? Nephrol Dial Transplant 19(Suppl 1):i9-i13, 2004
11. AKHTAR I, GONZALEZ EA: Biologic effects of parathyroid hormone metabolites: Implications for renal bone disease. J Investig Med 52:51-57, 2004
12. SILVER J, BUSHINSKY D: Harnessing the parathyroids to create stronger bones. Curr Opin Nephrol Hypertens 13:471-476, 2004
13. FOLEY RN, PARFREY PS, SARNAK MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112-S119, 1998
14. FOLEY RN, PARFREY PS, SARNAK MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9(12 Suppl):S16-23, 1998
15. KOK M, CASE D, BILLINGSLY J: The use of bone scintigraphy to evaluate metastatic calcification caused by end-stage renal disease and secondary hyperparathyroidism. Clin Nucl Med 28:144-145, 2003
16. BRAUN J, OLDENDORF M, MOSHAGE W, et al: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27:394-401, 1996
17. GANESH SK, STACK AG, LEVIN NW, et al: Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131-2138, 2001
18. BLOCK GA, HULBERT-SHEARON TE, et al: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617, 1998
19. FORD JC, POPE JF, HUNT AE, et al: The effect of diet education on the laboratory values and knowledge of hemodialysis patients with hyperphosphatemia. J Ren Nutr 14:36-44, 2004
20. REINKE CM, BREITKREUTZ J, LEUENBERGER H: Aluminum in over-the-counter drugs: Risks outweigh benefits? Drug Saf 26:1011-1025, 2003
21. NOLAN CR, QUNIBI WY: Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients. Curr Opin Nephrol Hypertens 12:373-379, 2003
22. GOODMAN WG, GOLDIN J, KUIZON BD, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
23. CHERTOW GM, BURKE SK, LAZARUS JM, et al: Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29:66-71, 1997
24. CHERTOW GM, BURKE SK, RAGGI P, et al, FOR THE TREAT TO GOAL WORKING GROUP: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
25. QUNIBI WY, HOOTKINS RE, MCDOWELL LL, et al: Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 65:1914-1926, 2004
26. COLADONATO JA, SZCZECH LA, FRIEDMAN EA, et al: Does calcium kill ESRD patients - The skeptic's perspective. Nephrol Dial Transplant 17:229-232, 2002
27. MALLICK NP, BERLYNE GM: Arterial calcification after vitamin-D therapy in hyperphosphatemic renal failure. Lancet 2:1316-1320, 1968
28. BLOCK GA: The impact of calcimimetics on mineral metabolism and secondary hyperparathyroidism in end-stage renal disease. Kidney Int 87(Suppl):S131-S136, 2003
29. BLOCK GA, MARTIN KJ, DE FRANCISCO AL, et al: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-1525, 2004